RankAlpha logo
Back to Rankings

VVOS

Vivos TherapeuticsD
Nasdaq / Health Care Equipment & Services
Last Price
$0.08-$0.02 (-16.12%)
At close · 2026-11-16
View Chart

AI scenario view

RankAlpha Sentiment Codex
B+
Bull case
20%
Probability
Target price
$0.16
Analysis reference price unavailable
Analysis 2026-11-11 · RankAlpha Sentiment Codex
Most likely
B
Base case
40%
Probability
Target price
$0.08
Analysis reference price unavailable
Analysis 2026-11-11 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.03
Analysis reference price unavailable
Analysis 2026-11-11 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-11-11
Recent news sentiment (30D)
-32.0
Negative
Company
-
Unavailable
Macro
-32.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+44.8
Score

AI commentary

Recent company filings improve the prior listing-compliance picture but leave dilution and cash funding central. News coverage is thin. The packet supplies no verified recent analyst revisions, post-announcement price-reaction attribution, social coverage or dependable positioning measures; zero-valued sentiment fields denote unavailable inputs, not neutral readings.

RankAlpha Sentiment Codex - 2026-11-11
Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact
tentative
Confidence
-

AI events

2026-11-30eventNext filing must substantiate Nasdaq equity complianceHigh impact

Nasdaq determined on October 20 that Vivos met its minimum stockholders’ equity requirement, but warned that failure to evidence compliance in its next periodic report could lead to delisting proceedings. This resolves the earlier deficiency only conditionally. [#8-K-2026-10-21] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/form8-k.htm

2026-12-31catalystDebt exchange and preferred shares create dilution riskHigh impact

An August agreement provides for exchange of $2.86 million of note principal for up to 11.45 million common shares. The October SOD transaction was paid with convertible preferred stock rather than cash. Share issuance terms and selling pressure could outweigh debt relief or strategic benefits. [#8-K-2026-09-08] https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/form8-k.htm [#SEC-8K-2026-10-19] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/form8-k.htm

2027-06-30catalystSleep-service growth needs to reduce cash burnHigh impact

Company-reported Q2 revenue rose 35% to $5.2 million, driven by Nevada sleep-testing and treatment services, but June cash was only $1.8 million. Sustained service growth matters only if it improves funding needs. [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-11-11 • Updated nightlySource: Internal modelMethodology